CD38 antibodies in multiple myeloma: Back to the future

Blood

Volumn 131, Issue 1, 2018, Pages 13-29

  Van De Donk, Niels W C J ^a   Richardson, Paul G ^b   Malavasi, Fabio ^c,d,e  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF TURIN   (Italy)

^e University Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CD38 ANTIBODY; FC RECEPTOR; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG; ADP RIBOSYL CYCLASE/CYCLIC ADP RIBOSE HYDROLASE 1; CD38 PROTEIN, HUMAN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

ALLERGIC DISEASE; AUTOIMMUNE DISEASE; BLOOD TRANSFUSION; BONE MARROW; CANCER RESISTANCE; CLINICAL EVALUATION; DRUG EFFECT; DRUG MECHANISM; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFUSION RELATED REACTION; LABORATORY TEST; MANAGED CARE; MONOTHERAPY; MULTICENTER STUDY (TOPIC); MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; RETREATMENT; REVIEW; SOLID MALIGNANT NEOPLASM; TISSUE DISTRIBUTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY;

ADP-RIBOSYL CYCLASE 1; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA;

EID: 85040045284     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2017-06-740944     Document Type: Review

References (106)

1. Laubach JP, Richardson PG. CD38-targeted immunochemotherapy in refractory multiple myeloma: a new horizon. Clin Cancer Res. 2015;21(12):2660-2662.
2. Reinherz EL, Kung PC, Goldstein G, Levey RH, Schlossman SF. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc Natl Acad Sci USA. 1980;77(3): 1588-1592.
3. Terhorst C, van Agthoven A, LeClair K, Snow P, Reinherz E, Schlossman S. Biochemical studies of the human thymocyte cell-surface antigens T6, T9 and T10. Cell. 1981;23(3): 771-780.
4. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk Res. 2001;25(1):1-12.
5. Krejcik J, Casneuf T, Nijhof IS, et al. Daratumumab depletes CD381 immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128(3):384-394.
6. Crowell PD, Goldstein AS. Functional evidence that progenitor cells near sites of inflammation are precursors for aggressive prostate cancer. Mol Cell Oncol. 2017;4(2): e1279723.
7. Kotlikoff MI, Kannan MS, Solway J, et al. Methodologic advancements in the study of airway smooth muscle. J Allergy Clin Immunol. 2004;114(suppl 2):S18-S31.
8. Horenstein AL, Sizzano F, Lusso R, et al. CD38 and CD157 ectoenzymes mark cell subsets in the human corneal limbus. Mol Med. 2009;15(3-4):76-84.
9. Song EK, Lee YR, Kim YR, et al. NAADP mediates insulin-stimulated glucose uptake and insulin sensitization by PPARg in adipocytes. Cell Reports. 2012;2(6):1607-1619.
10. Alessio M, Roggero S, Funaro A, et al. CD38 molecule: structural and biochemical analysis on human T lymphocytes, thymocytes, and plasma cells. J Immunol. 1990;145(3): 878-884.
11. Malavasi F, Deaglio S, Funaro A, et al. Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiol Rev. 2008;88(3):841-886.
12. Deaglio S, Morra M, Mallone R, et al. Human CD38 (ADP-ribosyl cyclase) is a counterreceptor of CD31, an Ig superfamily member. J Immunol. 1998;160(1):395-402.
13. Muñoz P, Mittelbrunn M, de la Fuente H, et al. Antigen-induced clustering of surface CD38 and recruitment of intracellular CD38 to the immunologic synapse. Blood. 2008; 111(7):3653-3664.
14. Howard M, Grimaldi JC, Bazan JF, et al. Formation and hydrolysis of cyclic ADPribose catalyzed by lymphocyte antigen CD38. Science. 1993;262(5136):1056-1059.
15. Lee HC. Nicotinic acid adenine dinucleotide phosphate (NAADP)-mediated calcium signaling. J Biol Chem. 2005;280(40): 33693-33696.
16. Cagnetta A, Cea M, Calimeri T, et al. Intracellular NAD1 depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013;122(7):1243-1255.
17. Chillemi A, Quarona V, Antonioli L, Ferrari D, Horenstein AL, Malavasi F. Roles and modalities of ectonucleotidases in remodeling the multiple myeloma niche. Front Immunol. 2017;8:305.
18. Stevenson FK, Bell AJ, Cusack R, et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood. 1991;77(5):1071-1079.
19. Goldmacher VS, Bourret LA, Levine BA, et al. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Blood. 1994;84(9):3017-3025.
20. de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3): 1840-1848.
21. Overdijk MB, Verploegen S, Bögels M, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2): 311-321.
22. Overdijk MB, Jansen JH, Nederend M, et al. The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcg receptor-mediated cross-linking. J Immunol. 2016;197(3):807-813.
23. Lammerts van Bueren J, Jakobs D, Kaldenhoven N, et al. Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79 [abstract]. Blood. 2014;124(21). Abstract 3474.
24. Deckert J, Wetzel MC, Bartle LM, et al. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD381 hematologic malignancies. Clin Cancer Res. 2014;20(17): 4574-4583.
25. Jiang H, Acharya C, An G, et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia. 2016;30(2): 399-408.
26. Adams H III, Stevenaert F, Krejcik J, et al. High-parameter mass cytometry (CyTOF) evaluation of relapsed/refractory multiple myeloma (MM) Pts (Pts) treated with daratumumab supports immune modulation as a novel mechanism of action [abstract]. Blood. 2016;128(22). Abstract 4521.
27. Feng X, Zhang L, Acharya C, et al. Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma. Clin Cancer Res. 2017;23(15):4290-4300.
28. Usmani SZ, Diels J, Ito T, Mehra M, Khan I, Lam A. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: an adjusted treatment comparison. Am J Hematol. 2017; 92(8):E146-E152.
29. Lokhorst HM, Plesner T, Laubach JP, et al. Targeting CD38 with daratumumab monotherapy in multiple myeloma. N Engl J Med. 2015;373(13):1207-1219.
30. Lonial S, Weiss BM, Usmani SZ, et al. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet. 2016;387(10027):1551-1560.
31. Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma. Blood. 2016;128(1):37-44.
32. Nijhof IS, Groen RW, Noort WA, et al. Preclinical evidence for the therapeutic potential of CD38-targeted immunochemotherapy in multiple myeloma patients refractory to lenalidomide and bortezomib. Clin Cancer Res. 2015;21(12):2802-2810.
33. Clemens PL, Yan X, Lokhorst HM, et al. Pharmacokinetics of daratumumab following intravenous infusion in relapsed or refractory multiple myeloma after prior proteasome inhibitor and immunomodulatory drug treatment. Clin Pharmacokinet. 2017;56(8): 915-924.
34. Xu XS, Yan X, Puchalski T, et al. Clinical implications of complex pharmacokinetics for daratumumab dose regimen in patients with relapsed/refractory multiple myeloma. Clin Pharmacol Ther. 2017;101(6):721-724.
35. Usmani S, Nahi H, Mateos MV, et al. Openlabel, multicenter, dose escalation phase 1b study to assess the subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (PAVO) [abstract]. Blood. 2016;128(22). Abstract 1149.
36. Raab M, Chatterjee M, Goldschmidt H, et al. A phase I/IIa study of the CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma [abstract]. Blood. 2016;128(22). Abstract 1152.
37. Martin TG III, Richter J, Vij R, Cole C, Atanackovic D, Zonder J. A dose finding phase II trial of isatuximab (SAR650984, anti-CD38 mAb) as a single agent in relapsed/refractory multiple myeloma [abstract]. Blood. 2015;126(23). Abstract 509.
38. Richter J, Martin TG III, Vij R, et al. Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed/refractory multiple myeloma (RRMM) [abstract]. J Clin Oncol. 2016;34(suppl 15):8005.
39. Nijhof IS, Groen RW, Lokhorst HM, et al. Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab. Leukemia. 2015;29(10):2039-2049.
40. Nijhof IS, Casneuf T, van Velzen J, et al. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959-970.
41. de Haart SJ, van de Donk NW, Minnema MC, et al. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clin Cancer Res. 2013; 19(20):5591-5601.
42. de Haart SJ, Holthof L, Noort WA, et al. Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance. Haematologica. 2016;101(8): e339-e342.
43. Marra J, Du J, Hwang J, Wolf J, Martin TG III, Venstrom J. KIR and HLA genotypes influence clinical outcome in multiple myeloma patients treated with SAR650984 (anti-CD38) in combination with lenalidomide and dexamethasone [abstract]. Blood. 2014; 124(21). Abstract 2126.
44. Horenstein AL, Chillemi A, Quarona V, et al. NAD1-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model. Cells. 2015;4(3): 520-537.
45. An G, Jiang H, Acharya C, et al. SAR 650984, a therapeutic anti-CD38 monoclonal antibody, blocks CD38-CD31 interaction in multiple myeloma [abstract]. Blood. 2014; 124(21). Abstract 4729.
46. Chillemi A, Quarona V, Zito A, et al. Generation and characterization of microvesicles after daratumumab interaction with myeloma cells [abstract]. Blood. 2015;126(23). Abstract 1849.
47. Taylor RP, Lindorfer MA. Fcg-receptormediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood. 2015;125(5):762-766.
48. Palumbo A, Chanan-Khan A, Weisel K, et al; CASTOR Investigators. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8): 754-766.
49. Martin T, Strickland S, Glenn M, Zheng W, Daskalakis N, Mikhael J. SAR650984, a CD38 monoclonal antibody in patients with selected CD381 hematological malignancies: data from a dose-escalation phase I study [abstract]. Blood. 2013;122(21):284.
50. Raab M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M. A phase I/IIa study of the human anti-CD38 antibody MOR202 (MOR03087) in relapsed or refractory multiple myeloma (rrMM) [abstract]. J Clin Oncol. 2015;33(suppl):8574.
51. Cherkasova E, Espinoza L, Kotecha R, Reger R, Berg M, Aue G. Treatment of ex vivo expanded NK cells with daratumumab F(ab') 2 fragments protects adoptively transferred NK cells from daratumumab-mediated killing and augments daratumumab-induced antibody dependent cellular toxicity (ADCC) of myeloma [abstract]. Blood. 2015;126(23). Abstract 4244.
52. Casneuf T, Xu X, Adams H, et al. Pharmacodynamic relationship between natural killer cells and daratumumab exposure in relapsed/refractory multiple myeloma [abstract]. In: Proceedings from the EHA21 Congress; 10 June 2016; Copenhagen, Denmark. Abstract P286.
53. Alici E, Chrobok M, Lund J, et al. Rechallenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach. Br J Haematol. 2016;174(3):473-477.
54. van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J. 2011;1(10):e41.
55. van der Veer MS, de Weers M, van Kessel B, et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica. 2011;96(2): 284-290.
56. Boxhammer R, Steidl S, Endell J. Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide [abstract]. J Clin Oncol. 2015;33(suppl 15):8588.
57. Endell J, Boxhammer R, Steidl S. Synergistic in vitro activity of MOR202, a human CD38 antibody, in combination with pomalidomide [abstract]. Blood. 2014;124(21). Abstract 5712.
58. Bruns H, Jitschin R, Mougiakakos D, et al. Lenalidomide enhances MOR202 dependent macrophage-mediated effector functions via the vitamin D pathway [abstract]. Blood. 2015;126(23). Abstract 2203.
59. Dimopoulos MA, Oriol A, Nahi H, et al; POLLUX Investigators. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14): 1319-1331.
60. Usmani S, Dimopoulos M, Belch A, et al. Efficacy of daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma patients with 1 to 3 prior lines of therapy: updated analysis of Pollux [abstract]. Blood. 2016;128(22). Abstract 1151.
61. Avet-Loiseau H, Casneuf T, Chiu C, et al. Evaluation of minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) patients treated with daratumumab in combination with lenalidomide plus dexamethasone or bortezomib plus dexamethasone [abstract]. Blood. 2016; 128(22). Abstract 246.
62. San-Miguel J, Dimopoulos MA, Usmani S, et al. Depth of response and MRD with daratumumab plus lenalidomide and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in RRMM: Pollux [abstract]. Clin Lymphoma Myeloma Leuk. 2017; 17(suppl 1):e17-e18.
63. Chiu C, Casneuf T, Axel A, et al. Daratumumab in combination with lenalidomide plus dexamethasone induces clonality increase and T-cell expansion: results from a phase 3 randomized study (POLLUX) [abstract]. Blood. 2016;128(22). Abstract 4531.
64. Martin T, Baz R, Benson DM, et al. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;129(25): 3294-3303.
65. Chatterjee M, Raab MS, Goldschmidt H, et al. A phase I/IIa study of the CD38 antibody MOR202 in combination with pomalidomide or lenalidomide in patients with relapsed or refractory multiple myeloma [abstract]. Clin Lymphoma Myeloma Leuk. 2017;17(suppl 1):e61.
66. Chari A, Suvannasankha A, Fay J, et al. Phase 1b study of daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma (RRMM) with$2 prior lines of therapy [abstract]. Clin Lymphoma Myeloma Leuk. 2017;17(suppl 1): e14-e15.
67. Richardson P, Mikhael J, Usmani S, Raje N, Bensinger W, Campana F. Preliminary results from a phase Ib study of isatuximab in combination with pomalidomide and dexamethasone in relapsed and refractory multiple myeloma [abstract]. Blood. 2016; 128(22):2123.
68. Moreno L, Zabaleta A, Alignani D, et al. Critical analysis on the mechanism of action (MoA) of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma (MM) [abstract]. Blood. 2016;128(22):2105.
69. Boxhammer R, Weirather J, Steidl C, Endell J. MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds [abstract]. Blood. 2015;126(23): 3015.
70. Mateos MV, Estell J, Barreto W, et al. Efficacy of daratumumab, bortezomib, and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory myeloma based on prior lines of therapy: updated analysis of castor [abstract]. Blood. 2016;128(22):1150.
71. Weisel KC, San Miguel J, Cook G, et al. Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (DVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status [abstract]. J Clin Oncol. 2017;35(suppl 15): 8006.
72. Martin TG III, Mannis G, Chari A, Munster P, Campana F, Hui A. Phase Ib study of isatuximab and carfilzomib in relapse and refractory multiple myeloma [abstract]. Blood. 2016;128(22):2111.
73. Jakubowiak AJ, Chari A, Lonial S, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study [abstract]. J Clin Oncol. 2017;35(suppl 15):8000.
74. Garćia-Guerrero E, Gogishvili T, Danhof S, et al. Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab. Blood. 2017;129(25): 3386-3388.
75. Nijhof IS, Lammerts van Bueren JJ, van Kessel B, et al. Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015;100(2):263-268.
76. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2): 271-285.
77. Chen L, Averett Byers L, Ullrich S, Wistuba I, Qin X, Gibbons D. CD38 as a novel immune checkpoint and a mechanism of resistance to the blockade of the PD-1/PD-L1 axis [abstract]. J Clin Oncol. 2017;35(suppl 7S). Abstract 79.
78. van de Donk NW, Moreau P, Plesner T, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood. 2016; 127(6):681-695.
79. Voorhees PM, Weiss B, Usmani S, et al. Management of infusion-related reactions following daratumumab monotherapy in patients with at least 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius) [abstract]. Blood. 2015;126(23):1829.
80. Chari A, Mark T, Krishnan A, et al. Use of montelukast to reduce infusion reactions in an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma [abstract]. Blood. 2016;128(22):2142.
81. van de Donk NW, Otten HG, El Haddad O, et al. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA). Clin Chem Lab Med. 2016; 54(6):1105-1109.
82. McCudden C, Axel AE, Slaets D, et al. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference. Clin Chem Lab Med. 2016;54(6):1095-1104.
83. Rosenberg AS, Bainbridge S, Pahwa R, Jialal I. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay. Clin Biochem. 2016;49(15):1202-1204.
84. Durie BG, Miguel JF, Blade J, Rajkumar SV. Clarification of the definition of complete response in multiple myeloma. Leukemia. 2015;29(12):2416-2417.
85. Caillon H, Irimia A, Simon J, et al. Overcoming the interference of daratumumab with immunofixation electrophoresis (IFE) using an industry-developed Dira test: hydrashift 2/4 daratumumab [abstract]. Blood. 2016;128(22):2063.
86. Murata K, McCash SI, Carroll B, et al. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood [published online ahead of print 21 September 2016]. Clin Biochem. doi:10.1016/j.clinbiochem.2016.09.015.
87. Chapuy CI, Aguad MD, Nicholson RT, et al; DARA-DTT Study Group for the BEST Collaborative. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016; 56(12):2964-2972.
88. Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545-1554.
89. Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55(6 Pt 2):1555-1562.
90. Sullivan HC, Gerner-Smidt C, Nooka AK, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood. 2017; 129(22):3033-3037.
91. Lintel NJ, Brown DK, Schafer DT, Tsimba-Chitsva FM, Koepsell SA, Shunkwiler SM. Use of standard laboratory methods to obviate routine dithiothreitol treatment of blood samples with daratumumab interference. Immunohematology. 2017;33(1):22-26.
92. Hannon JL, Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma. Transfusion. 2015;55(11):2770.
93. Murphy MF, Dumont LJ, Greinacher A; BEST Collaborative. Interference of new drugs with compatibility testing for blood transfusion. N Engl J Med. 2016;375(3):295-296.
94. Dimopoulos MA, Sonneveld P, Sun H. Daratumumab and blood-compatibility testing. N Engl J Med. 2016;375(25):2497-2498.
95. Chari A, Satta T, Tayal A, et al. Outcomes and management of red blood cell transfusions in multiple myeloma patients treated with daratumumab [abstract]. Blood. 2015; 126(23). Abstract 3571.
96. Sher T, Fenton B, Akhtar A, Gertz MA. First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood. 2016;128(15): 1987-1989.
97. Kaufman G, Witteles R, Wheeler M, et al. Hematologic responses and cardiac organ improvement in patients with heavily pretreated cardiac immunoglobulin light chain (AL) amyloidosis receiving daratumumab [abstract]. Blood. 2016;128(22). Abstract 4525.
98. Matas-Céspedes A, Vidal-Crespo A, Rodriguez V, et al. The human CD38 monoclonal antibody daratumumab shows antitumor activity and hampers leukemia-microenvironment interactions in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(6):1493-1505.
99. Hari P, Raj RV, Olteanu H. Targeting CD38 in refractory extranodal natural killer cell-T-cell lymphoma. N Engl J Med. 2016;375(15): 1501-1502.
100. Paulus A, Akhtar S, Bashir Y, et al. Drug resistance alters CD38 expression and in vitro response to daratumumab in waldenstrom macroglobulinemia cells [abstract]. Blood. 2016;128(22). Abstract 3018.
101. Dos Santos C, Xiaochuan S, Chenghui Z, et al. Anti-leukemic activity of daratumumab in acute myeloid leukemia cells and patientderived xenografts [abstract]. Blood. 2014; 124(21). Abstract 2312.
102. Tolbert V, Goldsby R, Huang J, et al. Daratumumab is effective in the treatment of refractory post-transplant autoimmune hemolytic anemia: a pediatric case report [abstract]. Blood. 2016;128(22). Abstract 4819.
103. Blankestijn MA, van de Donk N, Sasser K, Knulst AC, Otten HG. Could daratumumab be used to treat severe allergy? J Allergy Clin Immunol. 2017;139(5):1677-1678.
104. van Beurden-Tan CHY, Franken MG, Blommestein HM, Uyl-de Groot CA, Sonneveld P. Systematic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol. 2017; 35(12):1312-1319.
105. Moreau P, Mateos MV, Bladé J, et al. An open-label, multicenter, phase 1b study of daratumumab in combination with backbone regimens in patients with multiple myeloma [abstract]. Blood. 2014;124(21). Abstract 176.
106. Richardson P, Mikhael J, Usmani S, et al. Preliminary results from a phase Ib study of isatuximab in combination with pomalidomide (Pom) and dexamethasone (Dex) in relapsed and refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2017;17(suppl 1):e16-e17.